2025 Antibody Therapeutic & The 20th Frontiers in Biomedical Sciences Conference
2025抗體藥物暨第20屆前瞻生醫新知研討會
「2025 ATC抗體藥物暨第20屆前瞻生物醫學科學新知研討會」將於2025年5月26日至27日（星期一、二）假國家生技研究園區C棟2樓國際會議廳由中央研究院生醫轉譯研究中心、台灣抗體協會，財團法人台北市林榮耀教授學術教育基金會共同主辦。該研討會歷年來均吸引超過400位專家學者及產業人士共襄盛舉，現場交流熱絡，廣受好評。本年度更將延續此傳統，致力於促進學界與產業間的深度對話，並特別關注於提攜學子，為生技醫學新生代創造與頂尖專家學者互動及學習的寶貴機會。研討會自創辦以來，已成為分享前瞻生物醫學科學新知與探索創新合作模式的重要平台，其在推動生技醫學領域的影響力不容小覷。
首(26)日將聚焦各特色抗體藥物開發者由醫療需求出發，觀察全球市場發展概況，並針對新興抗體藥品的開發策略進行分享，同時就mRNA疫苗、抗體藥物、細胞治療等不同領域探討抗體應用，期能激盪出更多與會者對於新興抗體藥品之開發靈感；次(27)日之半日研討會，將聚焦創新生物醫學運用於生技產業，並邀請傑出學者進行學術生涯分享。
The "2025 Antibody Therapeutic & Frontiers in Biomedical Sciences Conference" will be held on May 26-27, 2025, at the National Biotechnology Research Park, organized by the Academia Sinica Biomedical Translation Research Center and the Taiwan Antibody Association. The conference attracts over 400 experts, scholars, and industry professionals annually, serving as a key platform for advancing antibody drug development and fostering academic-industry collaboration.
This year, the event will continue its tradition of facilitating in-depth discussions. On May 26, the focus will be on antibody therapeutic development, exploring global market trends and applications in mRNA vaccines, cell therapy, and more to inspire innovation. On May 27, the conference will highlight biomedical innovations in the biotech industry and feature distinguished scholars sharing their academic journeys.
Day 1: Antibody Therapeutic Conference (ATC)
Time | Agenda |
08:30 - 09:00 | Registration |
09:00 - 09:05 | Welcome Remarks Han-Chung Wu 吳漢忠 President, Taiwan Antibody Association (TAA) Director, National Biotechnology Research Park/Biomedical Translation Research Center (BioTReC), Academia Sinica |
09:05 - 09:10 | Moderator Lu-Hai Wang 王陸海院士 Academician, Academia Sinica |
09:10 - 09:40 | Lassograft Technology and Its Use in Novel Biotherapeutic Development Junichi Takagi 高木淳一 Professor, Institute for Protein Research, The University of Osaka, Japan |
09:40 - 10:10 | From Discovery to Delivery: The Multidisciplinary Path to Successful Antibody Drug Development Man-Cheong Fung President, Macafex Consulting LLC, USA |
10:10 - 10:35 | Break |
10:35 - 10:40 | Moderator Karen Wen 温國蘭 COO, GenomeFrontier Therapeutics, Inc. |
10:40 - 11:10 | Turning Darkness into Light: Harnessing Anti-Cytokine Autoantibodies for Therapeutic Applications Cheng-Lung Ku 顧正崙 Distinguished Professor / Director, Center for Molecular and Clinical Immunology, Chang Gung University |
11:10 - 11:40 | Advancing CAR/ TCR T with Non-Viral Quantum Engine Sareina Chiung-Yuan Wu 吳瓊媛 Founder/CEO, GenomeFrontier Therapeutics, Inc. |
11:40 - 13:30 | Lunch Seminar |
13:30 - 13:35 | 4th TAA General Assembly |
13:35 - 13:40 | Moderator Tse-Wen Chang 張子文 President, Immunwork Inc. |
13:40 - 14:10 | Challenges and Opportunities for ATMP (Advanced Therapy Medicinal Products) Development David Chang 張幼翔 CEO, Taiwan Bio-Manufacturing Corporation (TBMC) |
14:10 - 14:40 | Enhancing ADC Performance through Glycan Site-Specific Conjugation and Linker Chemistry David Teng-Yi Huang 黃鐙毅 Director, Medicinal Chemistry, OBI Pharma, Inc. |
14:40 - 15:25 | Break |
15:25 - 15:30 | Professor Tian-Lu Cheng Memorial Symposium 鄭添祿老師紀念研討會 |
15:30 - 16:00 | Anti-PEG Antibodies: The Good, the Bad, and the Ugly Steve Roffler 羅傅倫 Distinguished Research Fellow, Institute of Biomedical Sciences, Academia Sinica |
16:00 - 16:30 | Part 1. Armed-T Cell Technology: An Innovative Platform Inspired by Professor Tian-Lu Cheng Kuo-Hsiang Chuang 莊國祥 Professor, Taipei Medical University / CEO, CytoArm Ltd. Part 2. Revolutionizing Targeted Cancer Therapies: The Role of Universal Antibody Lock in Monoclonal Antibodies and Beyond Yun-Chi Lu 呂韻綺 CEO, PrecisemAb Biotech Co., Ltd. |
16:30 - 17:00 | Networking |
Day 2: The 20th Frontiers in Biomedical Sciences Conference
Time | Activities |
8:30-9:00 | Registration |
9:00-9:15 | Opening Remarks by Distinguished Guest Chien-Jen Chen 陳建仁 Former Vice President, Republic of China (Taiwan) / Academician, Academia Sinica |
9:15-9:20 | Moderator Yau-Huei Wei 魏耀揮 Former President, Mackay Medical College / Director, Jung-Yaw Lin Science and Education Foundation |
9:20-9:50 | Innovative Mass Spectrometry Development & Its Commercialization Chung Hsuan Chen 陳仲瑄院士 Board Director, iAnalyzer Inc. / Academician, Academia Sinica |
9:50-10:20 | Development of Therapeutic Monoclonal Antibodies Targeting Triple Negative Breast Cancer (TNBC) Lu-Hai Wang 王陸海院士 Vice President, China Medical University / Academician, Academia Sinica |
10:20-10:45 | Break |
10:45-10:50 | Moderator Hua-Lin Wu 吳華林 Director, Jung-Yaw Lin Science and Education Foundation |
10:50-11:20 | From Germ Theory to Germ Therapy Ming-Shiang Wu 吳明賢 Superintendent, National Taiwan University Hospital (NTUH) |
11:20-11:50 | The Role of 6mA DNA Methylation and lncRNA in Hypoxia-Induced Metastasis and Gene Expression Kou-Juey Wu 吳國瑞 Distinguished Chair Professor, Chang Gung Memorial Hospital at Linkou |
11:50-12:00 | Closing Remarks Han-Chung Wu 吳漢忠 Director & CEO of the Jung-Yaw Lin Science and Education Foundation Director, National Biotechnology Research Park/Biomedical Translation Research Center (BioTReC), Academia Sinica |
12:10-13:30 | Lunch (Invitation Only) |
14:00-17:00 | Workshop (Requires Separate Registration) |
※ 主辦單位保留活動變更權利
本次活動之主辦、協辦、贊助單位及TAA會員免費參加
● 主辦單位｜中央研究院生醫轉譯研究中心、台灣抗體協會、財團法人台北市林榮耀教授學術教育基金會
● 團體會員｜DCB生技中心、國光生技、免疫功坊、永昕生醫、智合精準醫學、全福生技、安肽生醫、台灣醣聯、台康生技、基亞生物科技、凌越生醫、研生生醫、台灣永生細胞、TBMC臺灣生物醫藥製造
● 協辦、贊助單位｜請見下方
